Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8996609 | 1.00 | SIGMAR1 (0.56) | SIGMAR1MAPTL3MBTL1GAAATM | |
| SCHEMBL8996599 | 1.00 | SIGMAR1 (0.56) | SIGMAR1MAPTL3MBTL1GAAATM | |
| SCHEMBL536970 | 0.86 | PPID (0.55) | SIGMAR1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL8936169 | 0.86 | PPID (0.55) | SIGMAR1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL4855884 | 0.85 | SMN1; SMN2 (0.44) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL4408805 | 0.85 | MEN1 (0.48) | SIGMAR1MAPTL3MBTL1ATMMEN1 | |
| SCHEMBL5394620 | 0.84 | SIGMAR1 (0.50) | SIGMAR1MAPTATMMEN1KMT2A | |
| SCHEMBL2852187 | 0.84 | SIGMAR1 (0.61) | SIGMAR1MAPTGAAMEN1KMT2A | |
| SCHEMBL4849306 | 0.84 | SIGMAR1 (0.61) | SIGMAR1MAPTGAAMEN1KMT2A | |
| SCHEMBL4855673 | 0.84 | SIGMAR1 (0.61) | SIGMAR1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349650-A | Method for synthesizing fenoterol intermediate by adopting microfluid technology | 大连万福制药有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-114349650-B | Method for synthesizing fenoterol intermediate by adopting microfluid technology | 大连万福制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-12-29 | — | — | US | disclosed |
| CN-114349650-A | Method for synthesizing fenoterol intermediate by adopting microfluid technology | 大连万福制药有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20040210064-A1 | Production method of beta-amino acid | AJINOMOTO CO., INC. (JP) | 2004-10-21 | — | — | US | disclosed |
| WO-2004009559-A2 | DIHYDROURACIL COMPOUNDS AS ANTI-ICTOGENIC OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-01-29 | — | — | WO | disclosed |
| EP-0690862-B1 | QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RES INST CHEM TECH (KR) | 2002-07-10 | — | — | EP | disclosed |
| US-5770597-A | ANTIBIOTIC | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1998-06-23 | — | — | US | disclosed |
| EP-0690862-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994015938-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-07-21 | — | — | WO | disclosed |
| US-4835175-A | Indole derivatives pharmaceutical preparations based thereon, and β-receptor stimulation therewith | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210064-A1 | Production method of beta-amino acid | BCAT2, BCAT1, AADAT | SIGMAR1 2171/4885MAPT 840/4885L3MBTL1 1615/4885 |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | SIGMAR1 1339/4885MAPT 4153/4885L3MBTL1 4360/4885 |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | SIGMAR1 2893/4885MAPT 1541/4885L3MBTL1 4621/4885 |
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4517/4885MAPT 3872/4885L3MBTL1 1105/4885 |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, HAVCR2, QDPR | SIGMAR1 1639/4885MAPT 4012/4885L3MBTL1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.